preterm birth and 17p efficacy - university of florida · practicum experience as part of the mph...

1
The authors would like to thank the March of Dimes Houston Office. The work presented was conducted as part of a practicum experience as part of the MPH program at the Texas A&M School of Public Health. Practicum completed January 2018 through May 2018. The ideas presented in this poster do not reflect the ideas of the March of Dimes. Results Conclusion Acknowledgements Materials and Methods Figure 3. Diagram of Factors contributing to adverse pregnancy outcomes. Adapted multifactorial conceptual model. Social/ Demographic Physiological Behavioral Adverse Pregnancy Outcome Race/ Ethnic Origin Geographic location Marital Status Economics Education Pregnancy related disorders History of Preterm Birth Cervical length Alcohol Use Support Smoking/ Tobacco use Prenatal care Preterm Birth and 17P Efficacy Kallie McWhinney,* Heather Butscher Department of Epidemiology and Biostatistics Texas A&M Health Science Center 17P is currently considered an effective and recommended intervention for the recurrence of preterm birth in women with a history of PTB. Public health entities, workers, educators must still work to break down barriers to access to ensure progesterone treatments are fully implemented and effectively administers during high-risk pregnancies. In the selected studies, the recurrent preterm birth rate of women taking 17P was between 24% to 39.6% Overall,17P has been shown to reduce PTB <32 or <34 weeks, but not always <37 weeks. 17P can reduce the rate of recurrent preterm birth even with partial compliance and late entry. Women with early 17-alpha hydroxyprogesterone caproate initiation had lower rates of major neonatal morbidity than those with later 17-alpha hydroxyprogesterone caproate initiation (1.5% vs 14.3%, P = .005). Non-Hispanic Black women were significantly less likely to be adherent to 17OHP-C (OR=0.16, CI 0.04-0.65). Public insurance was identified as a significant interaction placing Non-Hispanic Black women at increased risk of non-adherence (OR= 0.16, 95% CI 0.05-0.52). Figure 2 . Process of Inclusion of studies during the Systematic Literature Review. Adapted from PRISMA flow diagram. Preterm birth (PTB) increases risk for infant health problems, developmental issues, and mortality as compared to infants who are born full-term. The most significant risk factor for PTB is a history of preterm labor 1 . Several small trials suggest the administration of progesterone as an effective intervention to prevent sequential preterm labor. 17-alpha-hydroxyprogesterone caproate (17P) is a synthetic form of progesterone administered in weekly injections beginning between weeks 16-20. Despite the positive effects of 17P and the successes its implementation has shown, there still exists barriers to its referral and adherence. This poster aims to highlight those successes and barriers, and the March of Dimes initiatives that aids in the reduction of preterm birth. Figure 1. Graph depicting percentages of premature births in Texas and the United States. Data from National Center for Health Statistics and Texas Department of Health and Human Services. Payment Prior authorization Makena vs. compounded 17P Administrative Additional paperwork discourages usage Patient or Practitioner hesitation Barriers to 17P Access and Implementation Continued education of providers Creation of a statewide surveillance program to monitor 17P access through perinatal quality collaboratives Streamlining the ordering process for Makena/ 17P Faster identification of patients that are eligible for progesterone treatment Successes in 17P Access and Implementation Different policies by healthcare plans Late entry to prenatal care Transportation P r e T e r m B i r t h Figure 4. Successes and Barriers that affect17P access and implementation and the prevalence of preterm birth. Records identified by search string (17P and preterm birth) in Databases (ERIC, Scopus, Medline, Science Direct) (n = 9909 ) Records after inclusion criteria: English, No earlier than 2010, Peer-reviewed, Academic Journals and Reviews (n = 795 ) Records screened by key word (preterm birth), title, and additional reference searching (n = 56 ) Full-text articles assessed for eligibility (n = 46 ) Full-text articles excluded, (n = 26 ) Studies included (n = 20 ) Identification Screening Eligibility Included Introduction

Upload: others

Post on 22-Aug-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Preterm Birth and 17P Efficacy - University of Florida · practicum experience as part of the MPH program at the Texas A&M School of Public Health. Practicum completed January 2018

The authors would like to thank the March of Dimes Houston Office. The work presented was conducted as part of a practicum experience as part of the MPH program at the Texas A&M School of Public Health. Practicum completed January 2018 through May 2018. The ideas presented in this poster do not reflect the ideas of the March of Dimes.

Results

Conclusion

Acknowledgements

Materials and Methods

Figure 3. Diagram of Factors contributing to adverse pregnancy outcomes. Adapted multifactorial conceptual model.

Social/Demographic

Physiological

Behavioral

Adverse Pregnancy Outcome

Race/ Ethnic Origin

Geographic location

Marital Status

Economics

Education

Pregnancy related

disorders

History of

Preterm Birth

Cervical length

Alcohol Use

SupportSmoking/Tobacco

use

Prenatal care

Preterm Birth and 17P EfficacyKallie McWhinney,* Heather Butscher

Department of Epidemiology and BiostatisticsTexas A&M Health Science Center

• 17P is currently considered an effective and recommended intervention for the recurrence of preterm birth in women with a history of PTB.

• Public health entities, workers, educators must still work to break down barriers to access to ensure progesterone treatments are fully implemented and effectively administers during high-risk pregnancies.

• In the selected studies, the recurrent preterm birth rate of women taking 17P was between 24% to 39.6%

• Overall,17P has been shown to reduce PTB <32 or <34 weeks, but not always <37 weeks.

• 17P can reduce the rate of recurrent preterm birth even with partial compliance and late entry.

• Women with early 17-alpha hydroxyprogesterone caproate initiation had lower rates of major neonatal morbidity than those with later 17-alpha hydroxyprogesterone caproate initiation (1.5% vs 14.3%, P = .005).

• Non-Hispanic Black women were significantly less likely to be adherent to 17OHP-C (OR=0.16, CI 0.04-0.65). Public insurance was identified as a significant interaction placing Non-Hispanic Black women at increased risk of non-adherence (OR= 0.16, 95% CI 0.05-0.52).

Figure 2 . Process of Inclusion of studies during the Systematic Literature Review. Adapted from PRISMA flow diagram.

• Preterm birth (PTB) increases risk for infant health problems, developmental issues, and mortality as compared to infants who are born full-term.

• The most significant risk factor for PTB is a history of preterm labor1.• Several small trials suggest the administration of progesterone as an effective intervention to prevent

sequential preterm labor.• 17-alpha-hydroxyprogesterone caproate (17P) is a synthetic form of progesterone administered in

weekly injections beginning between weeks 16-20.• Despite the positive effects of 17P and the successes its implementation has shown, there still exists

barriers to its referral and adherence.• This poster aims to highlight those successes and barriers, and the March of Dimes

initiatives that aids in the reduction of preterm birth.

Figure 1. Graph depicting percentages of premature births in Texas and the United States. Data from National Center for Health Statistics and Texas Department of Health and Human Services.

• Payment• Prior authorization• Makena vs. compounded 17P• Administrative• Additional paperwork discourages usage • Patient or Practitioner hesitation

Barriers to 17P Access and

Implementation

• Continued education of providers• Creation of a statewide surveillance program to monitor 17P

access through perinatal quality collaboratives• Streamlining the ordering process for Makena/ 17P• Faster identification of patients that are eligible for

progesterone treatment

Successes in 17P Access and Implementation

• Different policies by healthcare plans

• Late entry to prenatal care

• Transportation Pre

Term

Birth

Figure 4. Successes and Barriers that affect17P access and implementation and the prevalence of preterm birth.

Records identified by search string (17P and preterm birth) in Databases (ERIC, Scopus, Medline, Science Direct)

(n = 9909 )

Records after inclusion criteria:English, No earlier than 2010, Peer-reviewed, Academic

Journals and Reviews(n = 795 )

Records screened by key word (preterm birth), title, and additional reference searching

(n = 56 )

Full-text articles assessed for eligibility

(n = 46 )

Full-text articles excluded, (n = 26 )

Studies included (n = 20 )

Identification

Screening

Eligibility

Included

Introduction